This protocol is judged by an institutional assessment board, an independent group that testimonials any scientific trials involving human beings. If a review consists of a Agenda I drug, after the board approves the protocol as ethical, the researchers need to apply for an investigational new drug (IND) quantity in the FDA.This informative article